Vaccine Maker Sinovac Enters Into Joint Venture In Chinese Coastal City Of Dalian
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Flush with cash following strong earnings for the third quarter and rising sales of the seasonal influenza vaccine Anflu, Beijing-based Sinovac Biotech aims to expand operations by investing in a joint venture in the Northeastern coastal city of Dalian, the company announced Nov. 25
You may also be interested in...
Beijing's Sinovac Receives Separate Approvals To Market Swine Flu Defense In Mexico, Avian Flu Vaccine In Hong Kong
HONG KONG - In a breakthrough in the Chinese company's drive to become a global vaccine player, Beijing-based Sinovac Biotech has received approval to distribute its swine influenza vaccine in Mexico and its avian flu vaccine in Hong Kong
China's Leading Vaccine Developer, Sinovac, Aims To Channel Expanding Earnings Into Acquisitions
BEIJING - While reporting a steep rise in profits for the second quarter of this year, the leadership of Chinese vaccine developer Sinovac Biotech said the cash-rich outfit is screening potential acquisition candidates across China
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).